TransCode Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for TransCode Therapeutics (RNAZ).

Price Target Range — 6 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$280Upside to Avg. PT+14675.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 16, 2025	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$20→$10
Mar 13, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$20
Feb 7, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$20
Feb 6, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$20
Dec 18, 2024	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$3→$20
Nov 15, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$3
Oct 24, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$3
Sep 6, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$3
Aug 15, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$3
May 29, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$3
May 16, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$3
Apr 16, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$3
Apr 3, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$3
Oct 24, 2023	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$3

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Lowers Price Target to $10

HC Wainwright & Co. analyst Emily Bodnar maintains TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and lowers the price target from $20 to $10.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $20 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Raises Price Target to $20

HC Wainwright & Co. analyst Emily Bodnar maintains TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and raises the price target from $3 to $20.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 price target.

Benzinga Newsdesk

TransCode Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

TransCode Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Lowers Price Target to $10

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Raises Price Target to $20

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

People Also Watch

People Also Watch

TransCode Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

TransCode Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Lowers Price Target to $10

PROHC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

PROHC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

PROHC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

PROHC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Raises Price Target to $20

PROHC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Lowers Price Target to $10

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

PRO
HC Wainwright & Co. Maintains Buy on TransCode Therapeutics, Raises Price Target to $20

PRO
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target